ASH Selects 11 Fellows for Research Award to Support Careers in Academic Hematology
(WASHINGTON, July 17, 2017) – The American Society of Hematology (ASH) today announced the names of 11 outstanding fellows selected to receive the 2017 ASH Research Training Award for Fellows (RTAF), a year-long program that aims to encourage careers in academic hematology by providing protected research time during training.
Each RTAF awardee will receive $70,000 to support a hematology research project throughout the program’s duration, from July 1, 2017, to June 30, 2018. The majority of the award money will support the recipient’s salary, with a percentage to be used for research supplies and travel to related scientific meetings, including the ASH annual meeting. Awards are targeted to two groups of researchers based on experience: a Junior Investigator award for second- and third-year fellows, and a Senior Investigator award for fourth- and fifth-year fellows.
“It’s often difficult to find sufficient time to conduct high-quality research during training,” said ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. “By supporting protected time for scientific exploration for these talented fellows, ASH is giving them the opportunity to conduct quality research, which will lead to academic appointments and future research funding.”
The 2017 ASH Research Training Award for Fellows recipients and their research topics are:
| Recipient | Research Topics |
| Akshay Sharma, MBBS University of Tennessee Knoxville, TN |
Enhancer dissection to understand fetal hemoglobin regulation |
| Allison Remiker, MD Cincinnati Children's Hospital Medical Center Cincinnati, OH |
Mechanisms linking fibrin(ogen) structure/function to tumor metastasis |
| Ami Patel, MD University of Utah Salt Lake City, UT |
Bone marrow stroma-based mechanisms of resistance in FLT3-ITD+ acute myeloid leukemia |
| Hojun Li, MD, PhD Boston Children's Hospital Boston, MA |
Deciding cell fate in hematopoiesis: asymmetric cell division in erythropoiesis as a model |
| Kandace Gollomp, MD University of Pennsylvania Philadelphia, PA |
HITing into the NET: A proposed role for neutrophils and NETs in the pathogenesis of heparin-induced thrombocytopenia |
| Kelly Bolton, MD, PhD Memorial Sloan-Kettering Cancer Center/New York Presbyterian New York, NY |
The impact of oncologic therapy on clonal hematopoiesis and secondary leukemia |
| Pamela Sung, MD, PhD University of Pennsylvania Philadelphia, PA |
Understanding mechanisms of primary resistance to targeted therapy in FLT3 mutated acute myeloid leukemia |
| Ryan Woods, MD Wake Forest University School of Medicine Winston-Salem, NC |
Development of a nanobody against wild-type and mutant calreticulin |
| Sarah Buckley, MD Fred Hutchinson Cancer Research Center Seattle, WA |
Disease-specific measurement of quality of life and adverse events in patients with acute myeloid leukemia |
| Seongseok Yun, MD, PhD University of South Florida, Morsani College of Medicine Tampa, FL |
The role of c-MYC and TFEB in the acute myeloid leukemia leukemogenesis |
| Tian Yi Zhang, MD, PhD Stanford University Stanford, CA |
Dissecting the mechanism of bone marrow failure in acute myeloid leukemia |
The American Society of Hematology (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.
CONTACT:
Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission